Balanced news tone
News Sentiment
ALEC sentiment intelligence
Alector Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
46
Balanced news tone
56 relevant articles
Price is moving more forcefully than the current news tone suggests.
80/100 classification confidence.
directly relevant articles
high-authority source matches
-21.8% over one week, +5.2% over four weeks, trend inactive, and below fair value.
Alector (ALEC) Proxy filing Summary
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
80/100 classification
One-week reaction
-21.8%
Price reacting lower
Trend fit
Trend inactive
5.2% over four weeks
Fair value
-55.8%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
7
Neutral
37
Negative
12
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Quartr
Direct company coverage
Alector (ALEC) Proxy filing Summary
Alector (ALEC) has announced its annual meeting for June 17, 2026, to be held virtually. Key proposals include the election of three directors, the ratification of Ernst & Young, LLP as the independent accounting firm, and an advisory vote on executive compensation, all recommend
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 14 Jul 2026 01:10
- Source
- Quartr
Quartr
Direct company coverage
Alector (ALEC) Goldman Sachs 45th Annual Global Healthcare Conference Summary
This article summarizes Alector's presentation at the Goldman Sachs 45th Annual Global Healthcare Conference, highlighting its strategic focus on eradicating neurodegenerative diseases by leveraging human genetics, immunology, and neuroscience. The company's clinical pipeline inc
- Tone
- Positive 73/100
- Event
- Market update
- Published
- 14 Jul 2026 00:00
- Source
- Quartr
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Sahm
Direct company coverage
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership
GSK's licensor Hansoh Pharmaceutical announced positive Phase 3 data for risvutatug rezetecan (Ris-Rez) in advanced or relapsed small-cell lung cancer, demonstrating improved overall survival. This marks the first positive Phase 3 survival data for a B7-H3-targeted antibody-drug
- Tone
- Negative 15/100
- Event
- Deals and strategy
- Published
- 12 Jul 2026 20:00
- Source
- Sahm
Investing.com Nigeria
Direct company coverage
Form 4 Alector Inc For: 9 July By Investing.com
This article announces the filing of a Form 4 by Alector Inc. on July 9th, as reported by Investing.com. It is a brief news item indicating insider transaction activity for the company Alector (ALEC). The article also lists various market data like indices, commodities, and stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 11:39
- Source
- Investing.com Nigeria
Market source
Direct company coverage
Alector and GSK partnership to end after dementia, Alzheimer's drug failures
Alector announced GSK is terminating their neuroscience collaboration agreement after two experimental antibody drugs for frontotemporal dementia and Alzheimer's disease failed in clinical trials. This decision follows setbacks for latozinemab in a late-stage study and nivisnebar
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 09 Jul 2026 21:51
- Source
- Market source
Stock Titan
Direct company coverage
Alector (ALEC) awards 20,000 RSUs to principal accounting officer
Alector, Inc. (ALEC) has awarded 20,000 Restricted Stock Units (RSUs) to its Principal Accounting Officer, Grace Wong-Sarad. These RSUs will vest in 12 equal quarterly installments starting September 1, 2026, and after this grant, Wong-Sarad holds 115,461 shares of common stock.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 19:51
- Source
- Stock Titan
Seeking Alpha
Direct company coverage
GSK Walks Away From Alector - Pipeline Reset Story Begins (NASDAQ:ALEC)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 14:05
- Source
- Seeking Alpha
European Medical Journal
Direct company coverage
GSK ends Alector alliance as both lead assets fail
GSK has terminated its five-year neuroscience collaboration with Alector after two experimental antibody drugs, latozinemab and nivisnebart, failed in clinical trials for frontotemporal dementia and Alzheimer's disease, respectively. While GSK exits the partnership, it continues
- Tone
- Negative 9/100
- Event
- Deals and strategy
- Published
- 09 Jul 2026 12:51
- Source
- European Medical Journal
BioPharma Dive
Direct company coverage
GSK ends brain drug alliance with Alector
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 11:45
- Source
- BioPharma Dive
MSN
Direct company coverage
Alector stock plummets 13% as GSK terminates neuroscience pact
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 05:44
- Source
- MSN
GuruFocus
Direct company coverage
Alector (ALEC) Shares Drop 13% Following Termination of GSK Collaboration
Alector Inc. (ALEC) shares dropped 13% after GSK terminated their collaboration on two experimental antibody drugs due to clinical trial failures, including latozinemab for frontotemporal dementia and nivisnebart for Alzheimer's. This setback highlights significant challenges for
- Tone
- Negative 28/100
- Event
- Market update
- Published
- 09 Jul 2026 06:39
- Source
- GuruFocus
Seeking Alpha
Direct company coverage
Alector stock plummets 13% as GSK terminates neuroscience pact (GSK:NYSE)
Alector's stock plunged 13% after GSK terminated their neuroscience collaboration due to clinical setbacks with two experimental antibody drugs. GSK's shares eased by 1.5% following the announcement. This decision highlights the risks associated with pharmaceutical drug developme
- Tone
- Negative 8/100
- Event
- Market update
- Published
- 09 Jul 2026 04:39
- Source
- Seeking Alpha
Stock Titan
Direct company coverage
Alector (ALEC) sees GSK end antibody collaboration while repaying $10.4M loan
Alector (ALEC) announced that GSK has terminated their 2021 collaboration and license agreement for progranulin-elevating antibodies latozinemab and nivisnebart, effective January 2, 2027. This decision follows the discontinuation of Phase 3 and Phase 2 trials for these programs
- Tone
- Negative 30/100
- Event
- Market update
- Published
- 08 Jul 2026 20:10
- Source
- Stock Titan
TradingView
Direct company coverage
Alector to End GSK Progranulin Collaboration; Repays $10.4 Million Hercules Loan
Alector announced the termination of its collaboration and license agreement with GSK for progranulin-elevating antibodies, effective January 2, 2027, following clinical trial setbacks. Concurrently, Alector repaid a $10.4 million loan to Hercules Capital, including principal, in
- Tone
- Negative 19/100
- Event
- Market update
- Published
- 08 Jul 2026 20:10
- Source
- TradingView
TradingView
Direct company coverage
0Z2 Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Alector, Inc. (0Z2) stock, based on analyst opinions. It includes financial data such as past earnings, revenue, net income, and EBITDA, along with important dates like the next earnings report. The piece also answers frequent
- Tone
- Positive 58/100
- Event
- Earnings
- Published
- 26 Jun 2026 20:09
- Source
- TradingView
TradingView
Direct company coverage
Alector, Inc. Actuals & Estimates (NASDAQ:ALEC)
This article provides an overview of Alector, Inc. (NASDAQ:ALEC) stock performance, financial estimates, and analyst forecasts. It covers metrics such as current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings dates. The informatio
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 06:09
- Source
- TradingView
TradingView
Direct company coverage
ALEC Forecast — Price Target — Prediction for 2027
This article provides a forecast, price target, and prediction for Alector, Inc. (ALEC) stock for 2027, based on analyst opinions and financial data. It covers current stock price, historical performance, earnings reports, market capitalization, and volatility, along with a discl
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 26 Jun 2026 05:40
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Alector, Inc. – NASDAQ:ALEC
The article displays the enterprise value to EBIT forward for Alector, Inc. (NASDAQ: ALEC). It appears to be a financial data snippet from a larger platform, possibly TradingView, focusing solely on this specific financial metric for the given company.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 21:11
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Alector, Inc. – NASDAQ:ALEC
This article briefly highlights the "Enterprise value to revenue forward" metric for Alector, Inc. (NASDAQ: ALEC). It appears to be a financial data point provided by TradingView, a financial markets platform. The content primarily focuses on the company's financial data and gene
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 17:40
- Source
- TradingView
TradingView
Direct company coverage
Price to book forward of Alector, Inc. – GETTEX:0Z2
The article discusses the "Price to book forward" metric for Alector, Inc. (GETTEX:0Z2), available on TradingView under its financial data section. It highlights that this specific financial data point is "Made by humans" and is part of the comprehensive information available for
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 10:11
- Source
- TradingView
Stock Titan
Direct company coverage
Alector (NASDAQ: ALEC) director receives new RSU and stock option awards
Alector (NASDAQ: ALEC) director Elizabeth A. Garofalo was granted new equity compensation on June 17, 2026. This included 28,700 restricted stock units (RSUs) vesting on June 17, 2027, or the date of the next annual stockholder meeting, and stock options for 9,450 shares vesting
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 19:39
- Source
- Stock Titan
TradingKey
Direct company coverage
Alector Inc (ALEC) Financial Health: Profitability & Balance Sheet Analysis
Alector Inc (ALEC) currently has a weak financial status and low operating efficiency, ranking 312 out of 389 in the Biotechnology & Medical Research industry with a financial score of 5.88. The company reported a significant year-over-year decrease in revenue (71.53%) and net pr
- Tone
- Negative 30/100
- Event
- Earnings
- Published
- 22 Jun 2026 17:09
- Source
- TradingKey
TradingKey
Direct company coverage
Alector Inc (ALEC) Institutional Confidence
Alector Inc (ALEC) has an institutional shareholding score of 7.00, placing it 81st in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 80.95%, showing a 17.91% decrease quarter-over-quarter. James Simons is the largest institutional sha
- Tone
- Positive 60/100
- Event
- Market update
- Published
- 19 Jun 2026 03:09
- Source
- TradingKey
Market source
Direct company coverage
Alector (ALEC) Stock Faces Mixed Analyst Target Changes On Tau Therapy Readthrough
Alector's fair value remains steady at US$3.10 per share, despite mixed analyst sentiment regarding tau-targeting therapies in Alzheimer's. While some analysts view Biogen's CELIA data as validating the approach and Alector's potential, others caution that the CELIA trial missed
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 19 Jun 2026 00:18
- Source
- Market source
TradingKey
Direct company coverage
Alector Inc (ALEC) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Alector Inc (ALEC), noting its current valuation score of 6.91 in the Biotechnology & Medical Research industry. It details the stock's current price, market cap, and P/E ratio, while indicating that P/B, P/S, and P/CF data have not y
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 09:39
- Source
- TradingKey
TradingKey
Direct company coverage
Alector Inc (ALEC) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Alector Inc (ALEC), including its current price momentum score, support and resistance levels. It details various technical indicators like MACD, RSI, and moving averages, offering buy, sell, or neutral signals. The analysis suggests
- Tone
- Negative 38/100
- Event
- Market update
- Published
- 18 Jun 2026 07:39
- Source
- TradingKey
TradingKey
Direct company coverage
Alector Inc (ALEC) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Alector Inc (ALEC), listing major shareholders and providing a breakdown of shareholder types, including investment advisors, hedge funds, and venture capital. It also presents institutional shareholding data over several quarters
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 05:38
- Source
- TradingKey
TradingKey
Direct company coverage
Alector Inc (ALEC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article concerns Alector Inc (ALEC) and its revenue breakdown by business segments, regional revenue, and profit contribution. However, the article states that relevant data for these categories have not been disclosed by the company yet. It primarily serves as a placeholder
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 03:38
- Source
- TradingKey
Stock Titan
Direct company coverage
Alector (ALEC) director receives 28,700 RSUs and 9,450-share option grant
Alector, Inc. director Richard H. Scheller received 28,700 restricted stock units (RSUs) and a stock option for 9,450 shares of common stock, as detailed in a recent Form 4 SEC filing. The RSUs vest on the earlier of June 17, 2027, or the company's next annual stockholder meeting
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 02:39
- Source
- Stock Titan